In this article
IGF-1 LR3 vs HGH is a comparison of two different points on the same hormone axis. HGH (somatropin) acts upstream at the growth hormone receptor and raises IGF-1 indirectly. IGF-1 LR3 is an engineered IGF-1 analogue that acts directly at the IGF-1 receptor and stays active longer than native IGF-1. They are not interchangeable.
- HGH works through the GH receptor first; IGF-1 LR3 skips that step and acts on IGF-1 receptors.
- HGH is an approved prescription drug for specific indications; IGF-1 LR3 is research-only in the United States.
- Both affect glucose and fluid balance, so glucose and IGF-1 monitoring are central.
- Robust long-term human data for IGF-1 LR3 are lacking, so benefit claims remain unproven.
IGF-1 LR3 vs HGH: side-by-side
| Factor | IGF-1 LR3 | HGH (somatropin) |
|---|---|---|
| Primary pathway | Direct IGF-1 receptor activity | GH receptor, then IGF-1 production |
| Half-life | Commonly cited around 20 to 30 hours | About 2 to 3 hours in plasma, with longer biological effects |
| Dose unit | Micrograms | International units (IU) |
| Research dose ranges | 50 mcg to 150 mcg once daily | 1 to 2 IU (wellness context), 2 to 4 IU (recomposition context) daily |
| Typical cycle reported | 8 to 12 weeks on, 2 to 4 off | Months; 6 on / 2 off or 3 to 6 months minimum |
| Regulatory status | Research only, not approved for human use | Prescription drug for specific indications |
| Main monitoring | Blood glucose, appetite, joints, swelling | Water retention, blood glucose |
Full pages: IGF-1 LR3 and HGH, and the dosage chart.
How the mechanisms differ
HGH
HGH raises circulating IGF-1 and influences lipolysis, connective tissue remodelling and broader endocrine adaptation. Because it sits upstream, effects tend to be systemic and take longer to settle.
IGF-1 LR3
IGF-1 LR3 is engineered to bind IGF-binding proteins less, which prolongs its active window. It signals directly, so responses can be more acute, and errors in dose escalation matter more. Direct IGF-1 activity also raises specific glucose-management considerations.
IGF-1 LR3 benefits
IGF-1 LR3 benefits are mainly framed around anabolic and recovery signalling, since IGF-1 is a mediator of tissue growth. The honest position is that the evidence is limited: Signal IQ’s page states long-term safety and efficacy have not been established through robust human clinical research. Claims about muscle growth or recovery come largely from mechanism and anecdote.
For wider context, see peptides for muscle growth.
IGF-1 LR3 before and after
There are no controlled before-and-after datasets for IGF-1 LR3 that can be cited here. Individual accounts vary widely, are self-reported, and are confounded by training, diet and other compounds, so they do not show what the peptide itself does. A more meaningful record is objective: fasting glucose, IGF-1 level, blood pressure and swelling, measured before and during any research protocol.
IGF-1 LR3 side effects
Signal IQ’s page advises monitoring blood glucose because IGF-1 acts on glucose metabolism, and watching for appetite changes, joint discomfort and swelling. A fuller adverse-effect profile has not been established. By mechanism, the main concerns are:
- Glucose lowering: IGF-1 has insulin-like effects, so low blood sugar is a particular concern with direct IGF-1 activity.
- Fluid retention and joint symptoms: reported across the GH axis, including carpal-tunnel-like symptoms.
- Growth effects: IGF-1 signalling promotes cell growth, which is why active cancer is a standard caution for GH-axis compounds.
HGH carries water retention and glucose changes as well, with higher doses linked to a higher likelihood of side effects. The strongest safety mistake described for both is escalating too fast without monitoring. See peptide side effects.
Monitoring checklist
- Fasting glucose or HbA1c
- Serum IGF-1
- Blood pressure
- Swelling, joint discomfort and sleep
The Bloodwork Panel Planner helps organise these baseline tests.
Using them together or alongside secretagogues
Combinations such as HGH with IGF-1 LR3, or IGF-1 LR3 with a GH secretagogue, are discussed in some circles. Stacking raises complexity and risk, and conservative starts with more frequent labs are the usual caution. Peptides that stimulate the pituitary instead of supplying GH are compared in ipamorelin vs sermorelin vs tesamorelin.
Frequently asked questions
Is IGF-1 LR3 stronger than HGH?
They are different tools. IGF-1 LR3 acts more directly and for longer, while HGH produces broader effects upstream. Neither is simply stronger.
What are IGF-1 LR3 benefits?
Anabolic and recovery signalling are the proposed benefits, but robust human evidence is lacking.
What are IGF-1 LR3 side effects?
Glucose changes, appetite shifts, joint discomfort and swelling are flagged, and long-term safety is not established.
Can IGF-1 LR3 and HGH be used together?
Some protocols do, but overlap raises risk and complexity, and close lab monitoring would be needed.
Why are the doses in different units?
HGH is standardised by biological activity in IU, while IGF-1 LR3 is dosed by mass in micrograms.
Is HGH or IGF-1 LR3 FDA-approved?
HGH is approved for specific indications. IGF-1 LR3 is research-only and not approved for human use.
Go deeper on Signal IQ
Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.
Ask PulseEducational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.



